News

The Cystic Fibrosis Foundation announced that Executive Vice President and Chief Operating Officer, Marc Ginsky, will be leaving the CF Foundation this summer to pursue other opportunities.

The Foundation welcomes new members to its Board of Trustees to advance its mission, including Trustees Jessica Boyd, MD; Dominic J. Caruso; and Paul Motenko and advisors James R. Butler, II; Eric Schneider, MD; and Jennifer L. Taylor-Cousar, MD. Long-serving members Sue L. Hook and Ted J. Torphy, PhD, have retired from the Board.

The Cystic Fibrosis Foundation celebrates the decision issued by the United States Supreme Court in California v. Texas, ultimately protecting the Affordable Care Act.

Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.

The U.S. Food and Drug Administration has approved the use of Trikafta ® (elexacaftor/tezacaftor/ivacaftor) for children ages 6 through 11 who have at least one copy of the F508del mutation or certain mutations in the CFTR gene that are responsive based on lab data. The U.S. Food and Drug Administrat

Observational study supported by the CF Foundation will monitor real-world experience with Trikafta